Tezacitabine
Tezacitabine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Golytely, Polyethylene glycol 3350 electrolytes (discontinued: Co-lav, Go-evac, Golytely, Osmoprep, Peg-lyte, Polyethylene glycol 3350 electrolytes, Visicol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
+
Sodium sulfate anhydrous
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GOLYTELY | Braintree Laboratories | N-019011 RX | 1984-07-13 | 1 products, RLD, RS |
Show 1 discontinued
Sodium phosphate
+
dibasic
+
anhydrous
+
Sodium phosphate
+
monobasic
+
monohydrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OSMOPREP | Salix Pharmaceuticals | N-021892 DISCN | 2006-03-16 | 1 products, RLD |
| VISICOL | Salix Pharmaceuticals | N-021097 DISCN | 2000-09-21 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 28tak gum care tooth | unapproved drug other | 2018-07-17 |
| akten | New Drug Application | 2024-04-19 |
| alka seltzer | OTC monograph final | 2012-11-09 |
| alka seltzer original | OTC monograph not final | 2019-07-08 |
| alka seltzer originial 1s blister pack | C200263 | 2023-11-05 |
| alka-seltzer | C200263 | 2023-12-15 |
| alka-seltzer extra strength | C200263 | 2023-12-04 |
| alka-seltzer hangover relief | C200263 | 2024-12-06 |
| alka-seltzer heartburn | C200263 | 2023-12-04 |
| alka-seltzer heartburn and pain | C200263 | 2024-12-13 |
Show 94 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| constipation | — | D003248 | K59.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
206 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | — | — | 1 | 1 | 1 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 2 | — | 1 | — | 3 |
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | 1 | 1 | 3 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | 2 | — | 3 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 2 | 1 | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 2 | 1 | 3 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | 1 | 1 | — | 3 |
| Colonoscopy | D003113 | — | — | — | — | — | 2 | 1 | 3 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | 1 | — | 2 |
| Headache | D006261 | — | R51 | — | — | 1 | 1 | — | 2 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 2 | 5 | 4 | — | — | 11 |
| Syndrome | D013577 | — | — | 2 | 2 | 6 | — | 1 | 10 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | 2 | — | — | 7 |
| Seizures | D012640 | — | G40.4 | 2 | — | 4 | — | — | 6 |
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | 1 | 2 | — | — | 3 |
| Abdominal pain | D015746 | EFO_0003766 | R10.9 | — | — | 1 | — | 2 | 3 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 2 | — | 1 | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 2 | 1 | — | — | 2 |
| Spasm | D013035 | — | M62.83 | — | — | 2 | — | — | 2 |
| Infantile spasms | D013036 | EFO_1000643 | G40.82 | — | — | 2 | — | — | 2 |
Show 36 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 4 | 5 | — | — | 2 | 9 |
| Neoplasms | D009369 | — | C80 | 5 | 4 | — | — | 1 | 9 |
| Healthy volunteers/patients | — | — | — | 3 | 1 | — | — | 5 | 9 |
| Colorectal neoplasms | D015179 | — | — | 2 | 5 | — | — | 2 | 7 |
| Adenocarcinoma | D000230 | — | — | 3 | 5 | — | — | — | 6 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 4 | 5 |
| Recurrence | D012008 | — | — | 2 | 2 | — | — | — | 4 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 2 | — | — | 2 | 4 |
| Leukemia | D007938 | — | C95 | 3 | 1 | — | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 1 | — | — | — | 3 |
Show 54 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | 2 | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | — | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | 1 | 2 |
| Lymphoma | D008223 | — | C85.9 | 2 | — | — | — | — | 2 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | 1 | 2 |
| Myeloid leukemia | D007951 | — | C92 | 2 | — | — | — | — | 2 |
| Preleukemia | D011289 | — | — | 2 | — | — | — | — | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | — | 1 | 2 |
Show 43 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperglycemia | D006943 | — | R73.9 | — | — | — | — | 3 | 3 |
| Fatigue | D005221 | — | R53.83 | — | — | — | — | 3 | 3 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 3 | 3 |
| Food diet and nutrition | D000066888 | — | — | — | — | — | — | 2 | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 2 | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 2 | 2 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | — | — | — | 2 | 2 |
| Skin aging | D015595 | EFO_0005422 | — | — | — | — | — | 2 | 2 |
| Postmenopause | D017698 | — | — | — | — | — | — | 1 | 1 |
| Respiratory signs and symptoms | D012818 | — | — | — | — | — | — | 1 | 1 |
Show 38 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tezacitabine |
| INN | tezacitabine |
| Description | Tezacitabine is a ribonucleotide reductase inhibitor. It is a synthetic purine nucleoside analogue with potential antineoplastic activity. It is used in synthetic DNA.
|
| Classification | Small molecule |
| Drug class | nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1.O |
Identifiers
| PDB | — |
| CAS-ID | 130306-02-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989496 |
| ChEBI ID | — |
| PubChem CID | 6435808 |
| DrugBank | — |
| UNII ID | 7607Y95N9S (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,768 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cidofovir, Docetaxel, Docetaxel anhydrous, Endrate, Levothyroxine sodium, Methylene blue inj, Osmoprep, Paroxetine hydrochloride anhydrous, Pnv prenatal vitamin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,876 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use